ES472742A1 - Procedimiento para la obtencion de derivados de alqueno - Google Patents

Procedimiento para la obtencion de derivados de alqueno

Info

Publication number
ES472742A1
ES472742A1 ES78472742A ES472742A ES472742A1 ES 472742 A1 ES472742 A1 ES 472742A1 ES 78472742 A ES78472742 A ES 78472742A ES 472742 A ES472742 A ES 472742A ES 472742 A1 ES472742 A1 ES 472742A1
Authority
ES
Spain
Prior art keywords
lower alkyl
preparation
pharmaceutical compositions
compositions containing
hydroxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES78472742A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of ES472742A1 publication Critical patent/ES472742A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/58—Preparation of carboxylic acid halides
    • C07C51/60—Preparation of carboxylic acid halides by conversion of carboxylic acids or their anhydrides or esters, lactones, salts into halides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procedimiento para la obtención de derivados de alqueno, de fórmula: **(Fórmula)** en la que bien R1 es un átomo de hidrógeno o bien un radical alquilo inferior y R2 es un radical alquilo inferior, o bien R1 y R2 estan unidos con el átomo de nitrógeno para formar un radical heterociclico; R3 es un átomo de halógeno o de hidrógeno, o un radical hidroxi o alquilo inferior, o es el radical buta-1 3-dienilo tal que junto con el anillo bencénico forme un radical naftilo; y n es 2, 3, 4, 5 ó 6 o una sal de adición de ácido farmaceuticamente aceptable, pero excluyendo el 1-(p-beta-dimetil-amino-etoxifenil)-1-p-hidroxi-fenil-2-fenilbut-1-eno y las sales de adición de ácido farmaceuticamente aceptables del mismo.
ES78472742A 1977-08-22 1978-08-22 Procedimiento para la obtencion de derivados de alqueno Expired ES472742A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB3509377 1977-08-22
GB336478 1978-01-27

Publications (1)

Publication Number Publication Date
ES472742A1 true ES472742A1 (es) 1979-02-16

Family

ID=26238259

Family Applications (1)

Application Number Title Priority Date Filing Date
ES78472742A Expired ES472742A1 (es) 1977-08-22 1978-08-22 Procedimiento para la obtencion de derivados de alqueno

Country Status (24)

Country Link
US (1) US4623660A (es)
EP (1) EP0002097B1 (es)
JP (1) JPS5444644A (es)
AR (1) AR218326A1 (es)
AT (1) AT358023B (es)
AU (1) AU524339B2 (es)
BG (1) BG30015A3 (es)
CA (1) CA1088950A (es)
CS (1) CS208659B2 (es)
DD (1) DD138313A5 (es)
DE (1) DE2860900D1 (es)
DK (1) DK370778A (es)
ES (1) ES472742A1 (es)
FI (1) FI782546A (es)
HU (1) HU177650B (es)
IE (1) IE47237B1 (es)
IL (1) IL55387A (es)
IT (1) IT1098276B (es)
NO (1) NO145657C (es)
NZ (1) NZ188151A (es)
PT (1) PT68458A (es)
RO (1) RO79083A (es)
SU (1) SU793382A3 (es)
YU (1) YU199478A (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3239610A1 (de) * 1982-10-26 1984-04-26 Klinge Pharma GmbH, 8000 München Neue 1,1,2-triphenyl-but-l-en-derivate, sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
EP0287690B1 (de) * 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
WO1994009764A1 (en) 1992-10-27 1994-05-11 Nippon Kayaku Kabushiki Kaisha Use of non steroidal anti estrogens for autoimmune diseases
DE69409961T2 (de) * 1993-09-24 1998-09-10 Merrell Pharma Inc Triarylethylenderivate zur therapeutischen verwendung
US5525633A (en) * 1993-09-24 1996-06-11 Merrell Dow Pharmaceuticals Inc. Triaryl-ethylene derivatives
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
EP0729363B1 (en) * 1994-06-27 2003-02-19 Neutron Therapies Inc. Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
US5658931A (en) * 1994-09-20 1997-08-19 Eli Lilly And Company Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
US5554628A (en) * 1994-09-20 1996-09-10 Eli Lilly And Company Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs
JPH10509962A (ja) * 1994-11-29 1998-09-29 ヘキスト・マリオン・ルセル・インコーポレイテツド 骨粗鬆症の治療および予防におけるトリアリール−エチレン誘導体の使用方法
US5691384A (en) * 1994-11-29 1997-11-25 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
US5763415A (en) 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
RU2214236C2 (ru) 1997-08-15 2003-10-20 Дьюк Юниверсити Способ профилактики или лечения эстрогензависимых заболеваний и расстройств
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
JP2002518329A (ja) 1998-06-16 2002-06-25 イーライ・リリー・アンド・カンパニー アセチルコリンレベルを増加させる方法
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US20020147187A1 (en) * 2001-02-22 2002-10-10 Schmidt Jonathan Martin 1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof
DE60334711D1 (de) * 2002-07-30 2010-12-09 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
US7531578B2 (en) * 2003-09-18 2009-05-12 City Of Hope Compounds and methods for treating breast cancer and other diseases
AU2004273658A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation (Warf) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005060946A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
JP5558358B2 (ja) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド メタボリック症候群用のｔｒａｎｓ−クロミフェン
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
EA201491530A1 (ru) * 2012-03-20 2015-07-30 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогенов и их применение
US9783519B2 (en) * 2015-06-18 2017-10-10 Hong Kong Baptist University Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
WO2019103989A1 (en) * 2017-11-22 2019-05-31 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized n,n-dialkylamino phenyl ethers and their method of use
AU2019223014B2 (en) 2018-02-21 2024-10-17 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US20230141863A1 (en) * 2021-11-10 2023-05-11 Northwestern University Small Molecule Inhibitors Targeting the Sodium Channel Tamoxifen Receptor and Uses Thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB879792A (en) * 1956-11-06 1961-10-11 Richardson Merrell Inc Preparation of substituted triphenylethylenes
BE635011A (es) 1962-07-17
BE637389A (es) 1962-09-13
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1128379A (en) 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
US3576874A (en) 1967-09-27 1971-04-27 Squibb & Sons Inc 2,2'''-((4,4 - diphenyl-3-buten- and - butylidene) bis (rho-phenyleneoxy))bis triethylamines
US3721712A (en) 1968-08-19 1973-03-20 Richardson Merrell Inc Aminoalkoxy-or aminomethyl-triarylalkenones

Also Published As

Publication number Publication date
IE781627L (en) 1979-02-22
BG30015A3 (en) 1981-03-16
US4623660A (en) 1986-11-18
IE47237B1 (en) 1984-01-25
IT7826930A0 (it) 1978-08-22
NO782768L (no) 1979-02-23
AU3900678A (en) 1980-02-21
AR218326A1 (es) 1980-05-30
NZ188151A (en) 1981-05-29
DK370778A (da) 1979-02-23
CS208659B2 (en) 1981-09-15
AU524339B2 (en) 1982-09-09
NO145657C (no) 1982-05-05
NO145657B (no) 1982-01-25
SU793382A3 (ru) 1980-12-30
PT68458A (pt) 1978-08-30
YU199478A (en) 1982-10-31
ATA610378A (de) 1980-01-15
CA1088950A (en) 1980-11-04
FI782546A (fi) 1979-02-23
DD138313A5 (de) 1979-10-24
IL55387A0 (en) 1978-10-31
RO79083A (ro) 1982-06-25
JPS5444644A (en) 1979-04-09
IT1098276B (it) 1985-09-07
EP0002097B1 (en) 1981-08-05
DE2860900D1 (en) 1981-11-05
EP0002097A1 (en) 1979-05-30
IL55387A (en) 1982-07-30
AT358023B (de) 1980-08-11
HU177650B (en) 1981-11-28

Similar Documents

Publication Publication Date Title
ES472742A1 (es) Procedimiento para la obtencion de derivados de alqueno
ES479933A1 (es) Un procedimiento para la preparacion de derivados de amino- piridina.
ES479820A1 (es) Procedimiento para la preparacion de isoquinoleinas.
ATE1418T1 (de) 1-hydrocarbyloxyphenyl-1.2-diphenylalkenderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzung.
FR2377367A1 (fr) Procede de preparation d'alcoxy-cetones
ES8400752A1 (es) "procedimiento para la preparacion de nuevos derivados de ciclofosfamida".
DE3274860D1 (en) Triazoloquinazolones and their salts, process and intermediates for preparing them, their use as medicines and compositions containing them
ES485733A1 (es) Procedimiento para la obtencion de derivados de esteres de 1,1,2-trifenilalqueno
PT75567A (fr) Procede de preparation de derives d'amino-2 tetrahydro-1,2,3,4 naphtalene et de compositions pharmaceutiques les contenant
DE3261515D1 (en) Benzopyranyl ethers, process for their preparation and medicine containing those compounds and intermediates
ES474367A1 (es) Procedimiento de preparacion de nuevos derivados del benzo- (d)tiazol.
FR2446841A1 (fr) Procede de preparation de 1a,3b-dihydroxy-d5-steroides
ES476529A1 (es) Procedimiento para la obtencion de derivados de 3-aminopro- poxiarilo.
DE3063450D1 (en) Theophylline derivatives, process for their preparation and medicaments containing these compounds
FR2383933A1 (fr) Procede de preparation de 2,4-dioxo-oxazolidines
DE3063991D1 (en) Aminopropanol derivatives, process for their preparation and pharmaceutical compositions containing these compounds
ES480562A1 (es) Un procedimiento para la preparacion de un nuevo vincaderi- vado dimero.
ES8504158A1 (es) Procedimiento para la preparacion de alcanolaminoxi-derivados de la 3,4-dihidro-2h-1,4-benzotiazin-3-ona
FR2357563A1 (fr) Nouvelles 7h-pyrrolo(3,2-f) quinazoline-1,3-diamines substituees en position 7, leur procede de preparation et medicament les contenant
ES2000614A6 (es) Procedimiento de obtencion de nuevos complejos de platino (ii) derivados del 2,3-dimercapto-2-butene-dinitrilato (2-)-s,s'"
ES472572A1 (es) Un procedimiento para la preparacion de derivados de morfi- nano 3-fenoxi-n-sustituidos levogiros
FR2312255A1 (fr) Nouvelles 2,4-benzothiazepines, leur preparation et leur application comme medicaments
IL67324A0 (en) New dehydrocardenolide derivatives,process for the preparation thereof and pharmaceutical preparations containing the same
DE3469358D1 (en) Novel 3-(4'-aminobutylamino)-propylamino-bleomycin derivatives, a process for their preparation and their use as medicaments
ES8105713A1 (es) Un procedimiento para la preparacion de los enatiomeros levogiro y dextrogiro de la 1-ciclopropil-metil-4-(3-metoxi-5h- dibenzo (a,d) ciclohepten-5-iliden) piperidina

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19990503